IRVINE, Calif.--(BUSINESS WIRE)--Mar. 7, 2019--
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical
technology company focused on the development and commercialization of
novel implantable Sacral Neuromodulation (“SNM”) devices for the
treatment of urinary
and bowel dysfunction, today announced that members of the
management team will participate in the following upcoming investor
Management is scheduled to present at the Barclays Global Healthcare
Conference, Thursday, March 14, at 9:30 am ET in Miami Beach, FL, and
will be available for one-on-one meetings.
Management will also be available for one-on-one meetings at the
Morgan Stanley Healthcare Corporate Access Day, Tuesday, March 19, in
To access the live webcast of the presentation at the Barclays Global
Healthcare Conference, please visit the Events & Presentations page of
the Investors section of the Company's website at ir.axonicsmodulation.com.
A replay of the webcast will be available shortly after the conclusion
of the presentation and will be archived on the Company's website for 90
About Axonics Modulation Technologies, Inc.
Axonics, based in Irvine, CA, is focused on the development and
commercialization of a novel implantable SNM system for patients with
urinary and bowel dysfunction. The Axonics r-SNM® System is the first
rechargeable Sacral Neuromodulation system approved for sale in Europe,
Canada and Australia, and the first SNM system to gain CE mark for
full-body MRI conditional labeling. Premarket Approval (PMA) for the
r-SNM System is currently pending with the U.S. FDA. For more
information, visit the Company’s website at www.axonicsmodulation.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190307005162/en/
Source: Axonics Modulation Technologies, Inc.
Axonics Modulation Technologies, Inc.
President & Chief Financial Officer
Investor & Media Contact